MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 206437 | Name: Elamipretide
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Elamipretide, also known as MTP 131, is a mitochondria-targeted peptide antioxidant. Elamipretide decreases inflammation and protect against a variety of neurological illnesses. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. Elamipretide Promotes Mitophagosome Formation and Prevents Its Reduction Induced by Nutrient Excess in INS1 β-cells.

Chemical Structure

Elamipretide
Elamipretide
CAS#736992-21-5 (free base)

Theoretical Analysis

MedKoo Cat#: 206437

Name: Elamipretide

CAS#: 736992-21-5 (free base)

Chemical Formula: C32H49N9O5

Exact Mass: 639.3857

Molecular Weight: 639.80

Elemental Analysis: C, 60.07; H, 7.72; N, 19.70; O, 12.50

Price and Availability

Size Price Availability Quantity
25mg USD 450.00 2 Weeks
50mg USD 750.00 2 Weeks
100mg USD 1,250.00 2 Weeks
200mg USD 1,950.00 2 Weeks
500mg USD 2,950.00 2 Weeks
1g USD 4,450.00 2 Weeks
2g USD 6,650.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
736992-21-5 (free base) 1334953-95-5 (acetate) 2244098-12-0 (3HCl)
Synonym
MTP-131; MTP 131; MTP131; Bendavia; RX-31; RX31; RX 31; SS-31 peptide; Elamipretide; D-Arg-Dmt-Lys-Phe-NH2.
IUPAC/Chemical Name
(S)-6-amino-N-((S)-1-amino-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-((R)-2-amino-5-guanidinopentanamido)-3-(4-hydroxy-2,6-dimethylphenyl)propanamido)hexanamide
InChi Key
SFVLTCAESLKEHH-WKAQUBQDSA-N
InChi Code
InChI=1S/C32H49N9O5/c1-19-15-22(42)16-20(2)23(19)18-27(41-29(44)24(34)11-8-14-38-32(36)37)31(46)39-25(12-6-7-13-33)30(45)40-26(28(35)43)17-21-9-4-3-5-10-21/h3-5,9-10,15-16,24-27,42H,6-8,11-14,17-18,33-34H2,1-2H3,(H2,35,43)(H,39,46)(H,40,45)(H,41,44)(H4,36,37,38)/t24-,25+,26+,27+/m1/s1
SMILES Code
O=C(N)[C@H](CC1=CC=CC=C1)NC([C@H](CCCCN)NC([C@H](CC2=C(C)C=C(O)C=C2C)NC([C@@H](CCCNC(N)=N)N)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
Soluble in DMSO, not in water 0.0 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 639.80 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hong S, Ghandriz R, Siddiqi S, Zhu XY, Saadiq IM, Jordan KL, Tang H, Ali KA, Lerman A, Eirin A, Lerman LO. Effects of Elamipretide on Autophagy in Renal Cells of Pigs with Metabolic Syndrome. Cells. 2022 Sep 16;11(18):2891. doi: 10.3390/cells11182891. PMID: 36139466; PMCID: PMC9496989. 2: Hornby B, Thompson WR, Almuqbil M, Manuel R, Abbruscato A, Carr J, Vernon HJ. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome. Orphanet J Rare Dis. 2022 Sep 2;17(1):336. doi: 10.1186/s13023-022-02469-5. PMID: 36056411; PMCID: PMC9438322. 3: Zhang X, Bowen E, Zhang M, Szeto HH, Deng XH, Rodeo SA. SS-31 as a Mitochondrial Protectant in the Treatment of Tendinopathy: Evaluation in a Murine Supraspinatus Tendinopathy Model. J Bone Joint Surg Am. 2022 Aug 18. doi: 10.2106/JBJS.21.01449. Epub ahead of print. PMID: 35984013. 4: Zhang P, Chen Y, Zhang S, Chen G. Mitochondria-Related Ferroptosis Drives Cognitive Deficits in Neonatal Mice Following Sevoflurane Administration. Front Med (Lausanne). 2022 Jul 22;9:887062. doi: 10.3389/fmed.2022.887062. PMID: 35935755; PMCID: PMC9355652. 5: Mitchell W, Tamucci JD, Ng EL, Liu S, Birk AV, Szeto HH, May ER, Alexandrescu AT, Alder NN. Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds. Elife. 2022 Aug 1;11:e75531. doi: 10.7554/eLife.75531. PMID: 35913044; PMCID: PMC9342957. 6: Zhang X, Zhang Y, Zhang M, Nakagawa Y, Caballo CB, Szeto HH, Deng XH, Rodeo SA. Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model. Am J Sports Med. 2022 Aug;50(10):2805-2816. doi: 10.1177/03635465221107943. Epub 2022 Jul 21. PMID: 35862638. 7: Zheng Z, Lei C, Liu H, Jiang M, Zhou Z, Zhao Y, Yu CY, Wei H. A ROS- Responsive Liposomal Composite Hydrogel Integrating Improved Mitochondrial Function and Pro-Angiogenesis for Efficient Treatment of Myocardial Infarction. Adv Healthc Mater. 2022 Jul 18:e2200990. doi: 10.1002/adhm.202200990. Epub ahead of print. PMID: 35848825. 8: Wang W, Tran PV. Mitochondrial pharmacotherapy during pregnancy and lactation in an ADPKD mouse model: a win for both mothers and their offspring. Kidney Int. 2022 May;101(5):870-872. doi: 10.1016/j.kint.2022.02.008. PMID: 35461611. 9: Whitson JA, Johnson R, Wang L, Bammler TK, Imai SI, Zhang H, Fredrickson J, Latorre-Esteves E, Bitto A, MacCoss MJ, Rabinovitch PS. Age-related disruption of the proteome and acetylome in mouse hearts is associated with loss of function and attenuated by elamipretide (SS-31) and nicotinamide mononucleotide (NMN) treatment. Geroscience. 2022 Jun;44(3):1621-1639. doi: 10.1007/s11357-022-00564-w. Epub 2022 Apr 13. PMID: 35416576; PMCID: PMC9213586. 10: Mason SA, Wadley GD, Keske MA, Parker L. Effect of mitochondrial-targeted antioxidants on glycaemic control, cardiovascular health, and oxidative stress in humans: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2022 Jun;24(6):1047-1060. doi: 10.1111/dom.14669. Epub 2022 Mar 3. PMID: 35165982; PMCID: PMC9314850. 11: Schwemmlein J, Maack C, Bertero E. Mitochondria as Therapeutic Targets in Heart Failure. Curr Heart Fail Rep. 2022 Apr;19(2):27-37. doi: 10.1007/s11897-022-00539-0. Epub 2022 Feb 11. PMID: 35147851; PMCID: PMC9023431. 12: Nhu NT, Xiao SY, Liu Y, Kumar VB, Cui ZY, Lee SD. Neuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodegeneration. Front Integr Neurosci. 2022 Jan 17;15:747901. doi: 10.3389/fnint.2021.747901. PMID: 35111001; PMCID: PMC8801496. 13: Obi C, Smith AT, Hughes GJ, Adeboye AA. Targeting mitochondrial dysfunction with elamipretide. Heart Fail Rev. 2022 Sep;27(5):1925-1932. doi: 10.1007/s10741-021-10199-2. Epub 2022 Jan 17. PMID: 35037146. 14: Daneshgar N, Liang PI, Lan RS, Horstmann MM, Pack L, Bhardwaj G, Penniman CM, O'Neill BT, Dai DF. Elamipretide treatment during pregnancy ameliorates the progression of polycystic kidney disease in maternal and neonatal mice with PKD1 mutations. Kidney Int. 2022 May;101(5):906-911. doi: 10.1016/j.kint.2021.12.006. Epub 2021 Dec 22. PMID: 34953771; PMCID: PMC9038630. 15: Alam NM, Douglas RM, Prusky GT. Treatment of age-related visual impairment with a peptide acting on mitochondria. Dis Model Mech. 2022 Mar 1;15(3):dmm048256. doi: 10.1242/dmm.048256. Epub 2022 Feb 21. PMID: 34766182; PMCID: PMC8891924. 16: Shankland SJ, Wang Y, Shaw AS, Vaughan JC, Pippin JW, Wessely O. Podocyte Aging: Why and How Getting Old Matters. J Am Soc Nephrol. 2021 Nov;32(11):2697-2713. doi: 10.1681/ASN.2021050614. PMID: 34716239; PMCID: PMC8806106. 17: Thompson R, Jefferies J, Wang S, Pu WT, Takemoto C, Hornby B, Heyman A, Chin MT, Vernon HJ. Current and future treatment approaches for Barth syndrome. J Inherit Metab Dis. 2022 Jan;45(1):17-28. doi: 10.1002/jimd.12453. Epub 2021 Nov 10. PMID: 34713454. 18: Sabbah HN. Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid. Heart Fail Rev. 2022 Sep;27(5):1911-1923. doi: 10.1007/s10741-021-10177-8. Epub 2021 Oct 8. PMID: 34623544; PMCID: PMC9388406. 19: Nashine S. Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD). Cells. 2021 Sep 19;10(9):2483. doi: 10.3390/cells10092483. PMID: 34572131; PMCID: PMC8464988. 20: Whitson JA, Martín-Pérez M, Zhang T, Gaffrey MJ, Merrihew GE, Huang E, White CC, Kavanagh TJ, Qian WJ, Campbell MD, MacCoss MJ, Marcinek DJ, Villén J, Rabinovitch PS. Elamipretide (SS-31) treatment attenuates age-associated post- translational modifications of heart proteins. Geroscience. 2021 Oct;43(5):2395-2412. doi: 10.1007/s11357-021-00447-6. Epub 2021 Sep 4. PMID: 34480713; PMCID: PMC8599536.